002020 Stock Overview
Zhejiang Jingxin Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 002020 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Zhejiang Jingxin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.29 |
| 52 Week High | CN¥13.99 |
| 52 Week Low | CN¥8.28 |
| Beta | 0.11 |
| 1 Month Change | -2.85% |
| 3 Month Change | -3.53% |
| 1 Year Change | 1.40% |
| 3 Year Change | 30.61% |
| 5 Year Change | 35.55% |
| Change since IPO | 25.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002020 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -6.1% | -3.2% | -4.8% |
| 1Y | 1.4% | -9.3% | 5.0% |
Return vs Industry: 002020 exceeded the CN Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: 002020 underperformed the CN Market which returned 5% over the past year.
Price Volatility
| 002020 volatility | |
|---|---|
| 002020 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002020 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002020's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,909 | Jin Zhiping | www.jingxinpharm.com |
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products.
Zhejiang Jingxin Pharmaceutical Co., Ltd. Fundamentals Summary
| 002020 fundamental statistics | |
|---|---|
| Market cap | CN¥10.58b |
| Earnings (TTM) | CN¥721.29m |
| Revenue (TTM) | CN¥4.28b |
14.7x
P/E Ratio2.5x
P/S RatioIs 002020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002020 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.28b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥2.16b |
| Other Expenses | CN¥1.44b |
| Earnings | CN¥721.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 03, 2025
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 50.43% |
| Net Profit Margin | 16.84% |
| Debt/Equity Ratio | 6.2% |
How did 002020 perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 20:34 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Jingxin Pharmaceutical Co., Ltd. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Chen | Chasing Securities |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |